NVCR NovoCure Limited
Healthcare$18.26+1.67%ClosedMarket Cap: $2.11B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
6.20
P/S
3.08
EV/EBITDA
-13.87
DCF Value
$-29.47
FCF Yield
-2.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.2%
Operating Margin
-27.2%
Net Margin
-25.7%
ROE
-50.8%
ROA
-22.0%
ROIC
-31.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $174.1M | 77.6% | $-67.4M | $-71.1M | $— | — |
| Q4 null | $174.3M | 75.8% | $-40.4M | $-24.5M | $— | — |
| FY null | $655.4M | 74.5% | $-153.8M | $-136.2M | $— | — |
| Q3 null | $167.2M | 73.2% | $-36.0M | $-37.3M | $— | — |
| Q2 null | $158.8M | 73.9% | $-39.5M | $-40.1M | $— | — |
| Q1 null | $155.0M | 75.1% | $-37.9M | $-34.3M | $— | — |
| Q4 null | $161.3M | 79.2% | $-63.3M | $-65.9M | $— | — |
| FY null | $605.2M | 77.3% | $-170.5M | $-168.6M | $— | — |
| Q3 null | $155.1M | 77.2% | $-32.1M | $-30.6M | $— | — |
| Q2 null | $150.4M | 77.0% | $-33.6M | $-33.4M | $— | — |
| Q1 null | $138.5M | 75.7% | $-41.5M | $-38.8M | $— | — |
| Q4 2023 | $133.8M | 75.7% | $-51.7M | $-47.1M | $-0.44 | — |